Budesonide-Loaded Hyaluronic Acid Nanoparticles for Targeted Delivery to the Inflamed Intestinal Mucosa in a Rodent Model of Colitis

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2022 Oct 7

PMID 36203483

Authors

Seyed Yaser Vafaei

Amir Hossein Abdolghaffari

Reza Mahjub

Seyyed Majid Eslami

Motahareh Esmaeili

Mohammad Abdollahi

Fatemeh Atyabi

Rassoul Dinarvand

Affiliations

Soon will be listed here.

Abstract

The aim of the present study was to investigate the therapeutic potential of budesonide- (BDS-) loaded hyaluronic acid nanoparticles (HANPs) for treatment of inflammatory bowel disease (IBD) using an acute model of colitis in rats. The therapeutic efficacy of BDS-loaded HANPs in comparison with an aqueous suspension of the drug with the same dose (30 g/kg) was investigated 48 h following induction of colitis by intrarectal administration of acetic acid 4% in rats. Microscopic and histopathologic examinations were conducted in inflamed colonic tissue. Tissue concentration of tumor necrosis factor (TNF)- was assessed by ELISA assay kit, while the activity of myeloperoxidase (MPO) was measured spectrophotometrically. Results from in vivo evaluations demonstrated that administrations of BDS-HANPs ameliorated the general endoscopic appearance, quite close to the healthy animals with no signs of inflammation and reduced the cellular infiltration, as well as the TNF- level, and the MPO activity. It was found that delivery by BDS-loaded HANPSs alleviated the induced colitis significantly better than the same dose of the free drug. These data further suggest the potential of HANPs as a targeted drug delivery system to the inflamed colon mucosa.

Citing Articles

Recognizing the biological barriers and pathophysiological characteristics of the gastrointestinal tract for the design and application of nanotherapeutics.

Li S, Wu T, Wu J, Chen W, Zhang D Drug Deliv. 2024; 31(1):2415580.

PMID: 39404464 PMC: 11485891. DOI: 10.1080/10717544.2024.2415580.

Targeting the Gut: A Systematic Review of Specific Drug Nanocarriers.

Garbati P, Picco C, Magrassi R, Signorello P, Cacopardo L, Serra M Pharmaceutics. 2024; 16(3).

PMID: 38543324 PMC: 10974668. DOI: 10.3390/pharmaceutics16030431.

Targeted delivery of budesonide in acetic acid induced colitis: impact on miR-21 and E-cadherin expression.

Seoudi S, Allam E, El-Kamel A, Elkafrawy H, El-Moslemany R Drug Deliv Transl Res. 2023; 13(11):2930-2947.

PMID: 37184747 PMC: 10545600. DOI: 10.1007/s13346-023-01363-2.

References

Vafaei S, Esmaeili M, Amini M, Atyabi F, Ostad S, Dinarvand R . Self assembled hyaluronic acid nanoparticles as a potential carrier for targeting the inflamed intestinal mucosa. Carbohydr Polym. 2016; 144:371-81. DOI: 10.1016/j.carbpol.2016.01.026. View

Lehr C . Lectin-mediated drug delivery: the second generation of bioadhesives. J Control Release. 2000; 65(1-2):19-29. DOI: 10.1016/s0168-3659(99)00228-x. View

Jubeh T, Barenholz Y, Rubinstein A . Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes. Pharm Res. 2004; 21(3):447-53. DOI: 10.1023/B:PHAM.0000019298.29561.cd. View

Lamprecht A, Schafer U, Lehr C . Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res. 2001; 18(6):788-93. DOI: 10.1023/a:1011032328064. View

Ahmed O, Abdel-Halim M, Farid A, Elamir A . Taurine loaded chitosan-pectin nanoparticle shows curative effect against acetic acid-induced colitis in rats. Chem Biol Interact. 2021; 351:109715. DOI: 10.1016/j.cbi.2021.109715. View

Carrette O, Favier C, Mizon C, Neut C, Cortot A, Colombel J . Bacterial enzymes used for colon-specific drug delivery are decreased in active Crohn's disease. Dig Dis Sci. 1995; 40(12):2641-6. DOI: 10.1007/BF02220454. View

Begue B, Wajant H, Bambou J, Dubuquoy L, Siegmund D, Beaulieu J . Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions. Gastroenterology. 2006; 130(7):1962-74. DOI: 10.1053/j.gastro.2006.03.022. View

Ali H, Weigmann B, Neurath M, Collnot E, Windbergs M, Lehr C . Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases. J Control Release. 2014; 183:167-77. DOI: 10.1016/j.jconrel.2014.03.039. View

Nugent S, Kumar D, Rampton D, Evans D . Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut. 2001; 48(4):571-7. PMC: 1728243. DOI: 10.1136/gut.48.4.571. View

10.

Antunes J, Seabra C, Domingues J, Teixeira M, Nunes C, Costa-Lima S . Drug Targeting of Inflammatory Bowel Diseases by Biomolecules. Nanomaterials (Basel). 2021; 11(8). PMC: 8401460. DOI: 10.3390/nano11082035. View

11.

Greenberg G, Feagan B, Martin F, Sutherland L, Thomson A, Williams C . Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med. 1994; 331(13):836-41. DOI: 10.1056/NEJM199409293311303. View

12.

Neurath M, Fuss I, Pasparakis M, Alexopoulou L, Haralambous S, Meyer zum Buschenfelde K . Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol. 1997; 27(7):1743-50. DOI: 10.1002/eji.1830270722. View

13.

Sartor R . Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006; 3(7):390-407. DOI: 10.1038/ncpgasthep0528. View

14.

Qelliny M, Aly U, Elgarhy O, Khaled K . Budesonide-Loaded Eudragit S 100 Nanocapsules for the Treatment of Acetic Acid-Induced Colitis in Animal Model. AAPS PharmSciTech. 2019; 20(6):237. DOI: 10.1208/s12249-019-1453-5. View

15.

Schmidt C, Lautenschlaeger C, Collnot E, Schumann M, Bojarski C, Schulzke J . Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: a first in vivo study in human patients. J Control Release. 2012; 165(2):139-45. DOI: 10.1016/j.jconrel.2012.10.019. View

16.

Kassab R, Elbaz M, Oyouni A, Mufti A, Theyab A, Al-Brakati A . Anticolitic activity of prodigiosin loaded with selenium nanoparticles on acetic acid-induced colitis in rats. Environ Sci Pollut Res Int. 2022; 29(37):55790-55802. DOI: 10.1007/s11356-022-19747-1. View

17.

Iborra M, Alvarez-Sotomayor D, Nos P . Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis. Clin Exp Gastroenterol. 2014; 7:39-46. PMC: 3921089. DOI: 10.2147/CEG.S34715. View

18.

Edsbacker S, Andersson P, Lindberg C, Paulson J, Ryrfeldt A, Thalen A . Liver metabolism of budesonide in rat, mouse, and man. Comparative aspects. Drug Metab Dispos. 1987; 15(3):403-11. View

19.

Collnot E, Ali H, Lehr C . Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J Control Release. 2012; 161(2):235-46. DOI: 10.1016/j.jconrel.2012.01.028. View

20.

Quetglas E, Armuzzi A, Wigge S, Fiorino G, Barnscheid L, Froelich M . Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. Eur J Clin Pharmacol. 2015; 71(7):773-99. DOI: 10.1007/s00228-015-1862-7. View